A Phase 3 interventional study of Pramipexol Extended Release and Pramipexol Immediate Release in Early Parkinson Disease (Early PD), sponsored by Boehringer Ingelheim. Completed at 95 sites in 14 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-07-17.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.
Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 3rd largest by enrollment, is one of 5 that started in 2007, is one of 11 in phase 3, and was the 10th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 12 · Phase 4 10
First in 1998; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 539 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 224 across the 26 interventional studies. Of the 24 that completed or were terminated, 15 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
42 studies in Parkinson Disease by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 42 finished, 22 (52%) have results posted.
Among the 42 studies in Parkinson Disease by Boehringer Ingelheim, this one is the 2nd largest by enrollment of the 20 interventional ones that give a count, is one of 7 that started in 2007, is one of 10 in phase 3, and was the 11th registered.
Boehringer Ingelheim’s Parkinson Disease studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing pramipexole in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 42 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of this trial conducted in early Parkinson's Disease (PD) patients are to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II and III combined), safety, and tolerability of Pramipexole Extended Release (ER) (in daily doses from 0.375mg to 4.5mg q.d.) in comparison to placebo, and to test for non-inferiority between the two formulations (ER and IR) of pramipexole.
In addition, the efficacy of Pramipexole Immediate Release (IR) will be compared to placebo, for assay sensitivity
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pramipexol Extended Release
Drug: Pramipexol Immediate Release
Drug: Placebo
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score
Activities of daily living are scored from 0-52 in UPDRS II, result of motor examination scored 0-108 in UPDRS III. A decrease in the score means improvement.
Time frame: baseline and after 33 weeks treatment
Percentage of Responders on the Clinical Global Impressions of Improvement (CGI-I) Scale
Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. Responders are the patients with 'much improved' and 'very much improved' on the scale
Time frame: after 18 weeks of treatment compared to baseline
Percentage of Responders on the Patients Global Impressions of Improvement (PGI-I) Scale
Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. Responders are the patients with 'much better' and 'very much better' on the score.
Time frame: after 18 weeks of treatment compared to baseline
UPDRS II+III Responder Rate (at Least 20% Improvement)
Responders are defined as at least 20% decrease in the UPDRS II+III score. UPDRS II+III ranges 0-160 scores from best to worse.
Time frame: after 33 weeks treatment
UPDRS Part I Change From Baseline
UPDRS I evaluates mentation behaviour and mood with a total score of 0-16. Decrease in the scores means improvement
Time frame: baseline and after 33 weeks treatment
UPDRS Part II Total Score
UPDRS II evaluates activities of daily living in a score 0-52. Decrease of the score means improvement
Time frame: after 33 weeks treatment
UPDRS Part III Total Score
UPDRS III is the result of a motor examination with the scores 0-108. A decrease in the scores means improvement
Time frame: after 33 weeks treatment
Beck's Depression Inventory Version I A
The Beck's Depression Inventory (BDI) is a 21-item self-rating scale that was originally designed as an instrument to assess the intensity of depressive symptoms (sadness, pessimism, sense of failure, dissatisfaction, guilt, expectation of punishment, dislike of self, self-accusation, suicidal ideation, episodes of crying, irritability, social withdrawal, indecisiveness, changes in body image, retardation, insomnia, fatigability, loss of appetite and weight, somatic preoccupation, low level of energy). Each item is scored from 0 (absent) to 3 (severe). The patients select the score which best describes their status in the last 7 days. Since its introduction in 1961, its use has been extended (also to PD patients) and today it is used also as a screening instrument as well as an outcome measure in depression treatment trials. The total score sums the 21 individual items yielding a score that can range from zero (minimal depression) to 63 (severe depression).
Time frame: after 33 weeks treatment
Likert Scale for Pain Related to PD
Patient assessed 11 units on a scale from 'no pain' to 'unbearable pain'. Decrease of the score means improvement
Time frame: after 33 weeks treatment
Parkinson's Disease Sleep Scale (PDSS)
PDSS is a self-rated instrument addressing 15 commonly reported symptoms associated with sleep disturbance on 15 visual analogue scales (VAS: 0 to 10 cm) each ranging from worst score ('awful or always' at the left extremity to the best score ('excellent or never' at the right extremity) An increase in the score means improvement. Worst possible score 0, best score 150)
Time frame: after 33 weeks treatment
Change From Baseline in Parkinson's Disease Quality of Life Questionnaire Total Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health which patients consider to be adversely affected by the disease. Higher scores are consistently associated with more severe symptoms of the disease such as tremor and stiffness, while lower scores indicate a better perceived health status. The 8 domains include: * mobility (e.g. fear of falling when walking): 10 items * activities of daily living (e.g. difficulty cutting food): 6 items * emotional well-being (e.g. feelings of isolation): 6 items * stigma (e.g. social embarrassment): 4 items * social support: 3 items * cognition: 4 items * communication: 3 items * bodily discomfort: 3 items. A total score is calculated by summing the responses to the 39 individual items and the total ranges from 0 (no problem at all) to 156 (maximum level of problem). A negative change in the total score indicates improvement.
Time frame: after 33 weeks treatment
Change From Baseline in European Quality of Life Visual Analog Scale
European Quality of Life Visual Analog Scale (EQ-5D VAS) is a 20 centimeter vertical analog scale assessing the patient's general health status with scores ranging from 0 (worst imaginable health) to 100 (perfect health). A positive change in the scale indicates improvement in health status.
Time frame: after 33 weeks treatment
Patients Who Started to Use L-Dopa Rescue Medication
L-dopa could be introduced as rescue medication based upon the clinical judgement of the investigator. descriptive on the Full Analysis Set (FAS) population
Time frame: from trial start on to any time before final assessment of the patient, up to 33 weeks
Number of Patients With Treatment Emergent Abnormal Behaviour as Indicated by the Modified Minnesota Impulsive Disorders Interview (mMIDI Questionnaire)
mMIDI is a semi-structured clinical interview to assess pathological gambling (12 questions, positive screen if patient answers 'yes' to question 1 and to at least 5 of the rest of the questions), compulsive buying (9 questions from 1a to 4c, positive screen if the patient answers 'yes' to 1a, 2a, 3a, and 4a) and compulsive sexual behaviour (4 questions, positive screen if patient answers 'yes' to question 1,2,3, or 4).
Time frame: from trial start on to any time before final assessment of the patient, up to 33 weeks
Possible Clinically Significant Abnormal Laboratory Parameters
The significant abnormality of values was based on standard criteria defined in appendix 16.1.10, LISTING 4 Criteria for clinically significant abnormalities based on normalized laboratory values.
Time frame: baseline and after 33 weeks of treatment
Clinical Relevant Abnormal Findings in Vital Signs and Physical Examination as Reported in Adverse Events
Time frame: baseline and after 33 weeks of treatment
| Milestone | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Started | 223 | 213 | 103 |
| Completed | 174 | 176 | 91 |
| Not completed | 49 | 37 | 12 |
| Withdrew: Adverse event | 24 | 20 | 4 |
| Withdrew: Lack of efficacy | 2 | 2 | 4 |
| Withdrew: Protocol violation | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 16 | 10 | 2 |
| Withdrew: Exclusion criteria, relocation | 4 | 3 | 0 |
Activities of daily living are scored from 0-52 in UPDRS II, result of motor examination scored 0-108 in UPDRS III. A decrease in the score means improvement.
| units on a scale | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score | -8.6 (-9.9 to -7.2) | -8.8 (-10.2 to -7.4) | -3.8 (-5.9 to -1.8) |
Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. Responders are the patients with 'much improved' and 'very much improved' on the scale
| Percentage of Participants | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Percentage of Responders on the Clinical Global Impressions of Improvement (CGI-I) Scale | 37 | 48 | 18 |
Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. Responders are the patients with 'much better' and 'very much better' on the score.
| Percentage of Participants | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Percentage of Responders on the Patients Global Impressions of Improvement (PGI-I) Scale | 35.6 | 23.8 | 12 |
Responders are defined as at least 20% decrease in the UPDRS II+III score. UPDRS II+III ranges 0-160 scores from best to worse.
| percentage of responders | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| UPDRS II+III Responder Rate (at Least 20% Improvement) | 68.5 | 65.7 | 48.5 |
UPDRS I evaluates mentation behaviour and mood with a total score of 0-16. Decrease in the scores means improvement
| units on a scale | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| UPDRS Part I Change From Baseline | 0.0 (-1.0 to 0.0) | 0.0 (-1.0 to 0.0) | 0.0 (-1.0 to 0.0) |
UPDRS II evaluates activities of daily living in a score 0-52. Decrease of the score means improvement
| units on a scale | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| UPDRS Part II Total Score | -2.2 (-2.6 to -1.7) | -2.4 (-2.9 to -2.0) | -0.9 (-1.5 to -0.3) |
UPDRS III is the result of a motor examination with the scores 0-108. A decrease in the scores means improvement
| units on a scale | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| UPDRS Part III Total Score | -6.4 (-7.4 to -5.4) | -6.4 (-7.4 to -5.4) | -2.8 (-4.2 to -1.4) |
The Beck's Depression Inventory (BDI) is a 21-item self-rating scale that was originally designed as an instrument to assess the intensity of depressive symptoms (sadness, pessimism, sense of failure, dissatisfaction, guilt, expectation of punishment, dislike of self, self-accusation, suicidal ideation, episodes of crying, irritability, social withdrawal, indecisiveness, changes in body image, retardation, insomnia, fatigability, loss of appetite and weight, somatic preoccupation, low level of energy). Each item is scored from 0 (absent) to 3 (severe). The patients select the score which best describes their status in the last 7 days. Since its introduction in 1961, its use has been extended (also to PD patients) and today it is used also as a screening instrument as well as an outcome measure in depression treatment trials. The total score sums the 21 individual items yielding a score that can range from zero (minimal depression) to 63 (severe depression).
| units on a scale | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Beck's Depression Inventory Version I A | -2.0 (-2.7 to -1.3) | -2.7 (-3.4 to -2.0) | -2.1 (-3.1 to -1.2) |
Patient assessed 11 units on a scale from 'no pain' to 'unbearable pain'. Decrease of the score means improvement
| units on a scale | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Likert Scale for Pain Related to PD | -0.2 (-0.4 to 0.1) | -0.1 (-0.4 to 0.1) | 0.2 (-0.2 to 0.5) |
PDSS is a self-rated instrument addressing 15 commonly reported symptoms associated with sleep disturbance on 15 visual analogue scales (VAS: 0 to 10 cm) each ranging from worst score ('awful or always' at the left extremity to the best score ('excellent or never' at the right extremity) An increase in the score means improvement. Worst possible score 0, best score 150)
| units on a scale | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Parkinson's Disease Sleep Scale (PDSS) | 2.3 (-0.4 to 5.0) | 5.6 (2.8 to 8.4) | 5.6 (1.8 to 9.4) |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health which patients consider to be adversely affected by the disease. Higher scores are consistently associated with more severe symptoms of the disease such as tremor and stiffness, while lower scores indicate a better perceived health status. The 8 domains include: * mobility (e.g. fear of falling when walking): 10 items * activities of daily living (e.g. difficulty cutting food): 6 items * emotional well-being (e.g. feelings of isolation): 6 items * stigma (e.g. social embarrassment): 4 items * social support: 3 items * cognition: 4 items * communication: 3 items * bodily discomfort: 3 items. A total score is calculated by summing the responses to the 39 individual items and the total ranges from 0 (no problem at all) to 156 (maximum level of problem). A negative change in the total score indicates improvement.
| units on a scale | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Change From Baseline in Parkinson's Disease Quality of Life Questionnaire Total Score | -4.1 (-6.1 to -2.0) | -6.5 (-8.6 to -4.5) | -2.1 (-4.9 to 0.8) |
European Quality of Life Visual Analog Scale (EQ-5D VAS) is a 20 centimeter vertical analog scale assessing the patient's general health status with scores ranging from 0 (worst imaginable health) to 100 (perfect health). A positive change in the scale indicates improvement in health status.
| units on a scale | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Change From Baseline in European Quality of Life Visual Analog Scale | 4.0 (1.4 to 7.6) | 6.6 (3.9 to 9.2) | 3.2 (-0.4 to 6.9) |
L-dopa could be introduced as rescue medication based upon the clinical judgement of the investigator. descriptive on the Full Analysis Set (FAS) population
| patients | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Patients Who Started to Use L-Dopa Rescue Medication | 15 | 9 | 22 |
mMIDI is a semi-structured clinical interview to assess pathological gambling (12 questions, positive screen if patient answers 'yes' to question 1 and to at least 5 of the rest of the questions), compulsive buying (9 questions from 1a to 4c, positive screen if the patient answers 'yes' to 1a, 2a, 3a, and 4a) and compulsive sexual behaviour (4 questions, positive screen if patient answers 'yes' to question 1,2,3, or 4).
| patients | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Number of Patients With Treatment Emergent Abnormal Behaviour as Indicated by the Modified Minnesota Impulsive Disorders Interview (mMIDI Questionnaire) | 4 | 3 | 1 |
The significant abnormality of values was based on standard criteria defined in appendix 16.1.10, LISTING 4 Criteria for clinically significant abnormalities based on normalized laboratory values.
| participants | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Haematocrit - decrease | 4 ± 9.8 | 3 ± 10.1 | 1 ± 10.7 |
| Haemoglobin - decrease | 11 | 6 | 1 |
| Red blood cell ct. - decrease | 1 | 0 | 0 |
| White blood cell ct. - decrease | 1 | 0 | 0 |
| Neut., poly (segs) - decrease | 2 | 0 | 0 |
| Eosinophils - increase | 6 | 3 | 3 |
| Neut., poly (segs), absol. - decrease | 1 | 0 | 0 |
| Sodium - decrease | 5 | 5 | 0 |
| Potassium - increase | 3 | 1 | 0 |
| Chloride - decrease | 2 | 0 | 0 |
| Alkaline phosphatase - increase | 0 | 1 | 0 |
| GGT - increase | 3 | 1 | 0 |
| Glucose - decrease | 3 | 0 | 0 |
| Glucose - increase | 1 | 1 | 0 |
| Cholesterol, total - increase | 0 | 0 | 1 |
| Creatinine - increase | 0 | 0 | 1 |
| Triglyceride - increase | 9 | 3 | 5 |
| Uric acid - increase | 3 | 1 | 2 |
| participants | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Hypertension | 6 | 7 | 5 |
| Orthostatic hypotension | 7 | 1 | 1 |
| Hypotension | 0 | 6 | 1 |
| Weight increased | 0 | 7 | 0 |
| Weight decreased | 2 | 3 | 0 |
| Blood pressure diastolic increased | 0 | 1 | 0 |
Collected over from trial start on to any time before final assessment of the patient, up to 33 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pramipexole Extended Release (PPX ER) | — | 16/223 (7.2%) | 142/223 (63.7%) |
| Pramipexole Immediate Release (PPX IR) | — | 11/213 (5.2%) | 133/213 (62.4%) |
| Placebo | — | 4/103 (3.9%) | 44/103 (42.7%) |
| Event | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| Vertigo positionalEar and labyrinth disorders | 0/223 | 0/213 | 1/103 |
| CholecystitisHepatobiliary disorders | 0/223 | 0/213 | 1/103 |
| CholelithiasisHepatobiliary disorders | 0/223 | 1/213 | 1/103 |
| Radius fractureInjury, poisoning and procedural complications | 0/223 | 0/213 | 1/103 |
| Back painMusculoskeletal and connective tissue disorders | 1/223 | 1/213 | 1/103 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/223 | 0/213 | 0/103 |
| Atrial fibrillationCardiac disorders | 0/223 | 1/213 | 0/103 |
| Myocardial infarctionCardiac disorders | 0/223 | 1/213 | 0/103 |
| PericarditisCardiac disorders | 0/223 | 1/213 | 0/103 |
| DiarrhoeaGastrointestinal disorders | 0/223 | 1/213 | 0/103 |
| Event | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo |
|---|---|---|---|
| SomnolenceNervous system disorders | 81/223 | 70/213 | 15/103 |
| NauseaGastrointestinal disorders | 48/223 | 51/213 | 9/103 |
| ConstipationGastrointestinal disorders | 31/223 | 25/213 | 2/103 |
| DizzinessNervous system disorders | 26/223 | 25/213 | 7/103 |
| Oedema peripheralGeneral disorders | 12/223 | 18/213 | 4/103 |
| NasopharyngitisInfections and infestations | 14/223 | 9/213 | 8/103 |
| HeadacheNervous system disorders | 7/223 | 15/213 | 6/103 |
| FatigueGeneral disorders | 14/223 | 11/213 | 4/103 |
| Back painMusculoskeletal and connective tissue disorders | 11/223 | 11/213 | 6/103 |
| Dry mouthGastrointestinal disorders | 12/223 | 8/213 | 1/103 |
| Age, Continuous(years) | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo | Total |
|---|---|---|---|---|
| Mean | 61.3 ± 9.8 | 61.7 ± 9.6 | 62.0 ± 9.6 | 61.6 ± 9.7 |
| Sex: Female, Male(Participants) | Pramipexole Extended Release (PPX ER) | Pramipexole Immediate Release (PPX IR) | Placebo | Total |
|---|---|---|---|---|
| Female | 96 | 92 | 52 | 240 |
| Male | 127 | 121 | 51 | 299 |
The record gives a start of May 2007 and a primary completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole